[HTML][HTML] Superior expansion and cytotoxicity of human primary NK and CAR-NK cells from various sources via enriched metabolic pathways
Y Yang, S Badeti, H Tseng, MT Ma, T Liu… - … Therapy Methods & …, 2020 - cell.com
Clinical success of chimeric antigen receptor (CAR) T cell immunotherapy requires the
engineering of autologous T cells, which limits the broader implementation of CAR cell …
engineering of autologous T cells, which limits the broader implementation of CAR cell …
Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways
Y Yang, S Badeti, H chi Tseng… - Molecular Therapy …, 2020 - researchwithrutgers.com
Liu and colleagues developed a novel approach to rapidly propagate human primary NK
and CAR-NK cells with superior expansion capability and in vivo cytotoxicity from various …
and CAR-NK cells with superior expansion capability and in vivo cytotoxicity from various …
[PDF][PDF] Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways
Y Yang, S Badeti, H Tseng, MT Ma, T Liu, JG Jiang… - researchgate.net
Clinical success of chimeric antigen receptor (CAR) T cell immunotherapy requires the
engineering of autologous T cells, which limits the broader implementation of CAR cell …
engineering of autologous T cells, which limits the broader implementation of CAR cell …
Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways.
Y Yang, S Badeti, HC Tseng, MT Ma, T Liu… - … therapy. Methods & …, 2020 - europepmc.org
Clinical success of chimeric antigen receptor (CAR) T cell immunotherapy requires the
engineering of autologous T cells, which limits the broader implementation of CAR cell …
engineering of autologous T cells, which limits the broader implementation of CAR cell …
Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways
Y Yang, S Badeti, HC Tseng, MT Ma… - … therapy. Methods & …, 2020 - pubmed.ncbi.nlm.nih.gov
Clinical success of chimeric antigen receptor (CAR) T cell immunotherapy requires the
engineering of autologous T cells, which limits the broader implementation of CAR cell …
engineering of autologous T cells, which limits the broader implementation of CAR cell …
[HTML][HTML] Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways
Y Yang, S Badeti, H Tseng, MT Ma, T Liu… - … Therapy. Methods & …, 2020 - ncbi.nlm.nih.gov
Clinical success of chimeric antigen receptor (CAR) T cell immunotherapy requires the
engineering of autologous T cells, which limits the broader implementation of CAR cell …
engineering of autologous T cells, which limits the broader implementation of CAR cell …
[HTML][HTML] Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways
Y Yang, S Badeti, H Tseng, MT Ma, T Liu… - … Therapy-Methods & …, 2020 - Elsevier
Clinical success of chimeric antigen receptor (CAR) T cell immunotherapy requires the
engineering of autologous T cells, which limits the broader implementation of CAR cell …
engineering of autologous T cells, which limits the broader implementation of CAR cell …
[PDF][PDF] Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways
Y Yang, S Badeti, H Tseng, MT Ma, T Liu, JG Jiang… - nakitherapeutics.com
Clinical success of chimeric antigen receptor (CAR) T cell immunotherapy requires the
engineering of autologous T cells, which limits the broader implementation of CAR cell …
engineering of autologous T cells, which limits the broader implementation of CAR cell …
Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways
Y Yang, S Badeti, H chi Tseng… - Molecular …, 2020 - mdanderson.elsevierpure.com
Liu and colleagues developed a novel approach to rapidly propagate human primary NK
and CAR-NK cells with superior expansion capability and in vivo cytotoxicity from various …
and CAR-NK cells with superior expansion capability and in vivo cytotoxicity from various …
Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways.
Y Yang, S Badeti, HC Tseng, MT Ma, T Liu… - … therapy. Methods & …, 2020 - europepmc.org
Clinical success of chimeric antigen receptor (CAR) T cell immunotherapy requires the
engineering of autologous T cells, which limits the broader implementation of CAR cell …
engineering of autologous T cells, which limits the broader implementation of CAR cell …